单克隆抗体（mAB）选择性地靶向白血病表面抗原，并通过阻断细胞表面受体或触发靶细胞的破坏来起作用。类似地，酶抑制剂结合复杂的分子平台，并诱导下游机制触发细胞死亡。它们被用于各种血液恶性肿瘤。然而，它们也作为生物制品引起严重的免疫介导反应，需要仔细监测。心血管效应包括心肌病、室壁功能障碍、心脏停跳和急性冠状动脉综合征。虽然有零散的单克隆抗体和酶抑制剂评价，但缺乏关于它们心血管风险概况的综合资源。我们根据文献提供初始筛选和连续监测的一般建议。版权所有 © 2023. Elsevier Inc. 发布。

Monoclonal antibodies (mAB) selectively target leukemia surface antigens and work by either blocking cell surface receptors or triggering the target cell's destruction. Similarly, enzyme inhibitors bind to complex molecular platforms and induce downstream mechanisms that trigger cell death. These are used in a variety of hematologic malignancies. Yet, they also elicit severe immune-mediated reactions as biological agents that require careful monitoring. Cardiovascular effects include cardiomyopathy, ventricular dysfunction, cardiac arrest, and acute coronary syndrome. While there have been scattered reviews of mAB and enzyme inhibitors, a consolidated resource regarding their cardiovascular risk profile is lacking. We provide general recommendations for initial screening and serial monitoring based on the literature.Copyright © 2023. Published by Elsevier Inc.